Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State...

Area of Science:

• Health Policy
• Pharmaceutical Economics
• Regulatory Science

Background:

• The US Food and Drug Administration (FDA) accelerated approval program is under scholarly review due to concerns regarding its oversight and implications for payers.
• State Medicaid programs face fiscal challenges from reimbursement obligations for accelerated approval products, influenced by evolving industry practices.

Purpose of the Study:

• To analyze the fiscal challenges faced by state Medicaid programs due to the FDA's accelerated approval pathway.
• To explore policy reform options that address the financial implications of accelerated approval products for Medicaid while balancing drug access and evidence of clinical benefit.

Main Methods:

• Review of existing literature on FDA accelerated approval and Medicaid reimbursement policies.
• Analysis of fiscal challenges and proposed policy reforms related to accelerated approval products.
• Examination of potential reform areas including formulary exclusion, rebates, value-based pricing, and consolidated purchasing.

Main Results:

• Industry's changing use of the accelerated approval program has exacerbated fiscal challenges for Medicaid.
• Existing reform strategies primarily focus on FDA pathway changes, neglecting state Medicaid implications.
• There is a critical need for policy reforms that consider both expedited drug approval and states' concerns about medication spending.

Conclusions:

• Policy makers should consider reforms to reimbursement for accelerated approval products, complementing FDA operational changes.
• Potential reforms include formulary exclusion, Medicaid rebates, value-based pricing, and consolidated purchasing.
• Policy proposals can help evaluate the trade-offs between patient access to novel medicines and healthcare costs.